SPRY
ARS Pharmaceuticals, Inc. (NASDAQ)
Healthcare — Biotechnology
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Strong Buy
1.0 / 5
4 analysts
$8.06
+$0.12 (+1.57%)
Target:
$29.25
(262.7%)
Sign in to add SPRY to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $800.88M |
| P/E Ratio (TTM) | - |
| Forward P/E | -9.45 |
| EPS (TTM) | $-2.00 |
| Dividend Yield | - |
| Profit Margin | -200.00% |
| Revenue Growth | 184.50% |
| ROE | -136.40% |
| Debt/Equity | 279.24 |
| Recommendation | Strong Buy 1.0 |
| Analyst Target | $29.25 |
| Analysts | 4 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 36.1 |
| Beta | 0.83 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $18.63 |
| 52-Week Low | $6.66 |
| 50-Day Avg | $8.70 |
| 200-Day Avg | $9.33 |
| Avg Volume | $1.80M |
| Volume | 11.6K |
Performance Analysis
NEUTRALSPRY presents a mixed picture with both positive and negative indicators.
~
Trading at 12% of its 52-week range.
~
RSI at 36.1 is in neutral territory.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Strong revenue growth of 184.5% year-over-year.
-
Operating at a loss with -200.0% margin.
+
Wall Street consensus is "Strong Buy" from 4 analysts.
+
Average analyst target of $29.25 implies 262.7% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:32 UTC
Back to Screener Export Report